RedHill Biopharma Ltd (RDHL)

[tykundegex]

These 2 slides from today's call say it all.

• BEKINDA® 24 mg is beneficial in the treatment of acute gastroenteritis and gastritis and can provide 24 hours of relief to dehydrated patients
who present to the Emergency Department with frequent vomiting
• The study shows that placement of an IV is not necessary to treat moderate to severe vomiting from gastroenteritis
• With the use of BEKINDA® patients can orally and comfortably self- rehydrate until resolution of the viral syndrome
• BEKINDA® 24 mg was also shown to be safe and well tolerated in patients
with acute gastroenteritis and gastritis


• If approved for marketing by FDA, BEKINDA® 24 mg could become the first 5-HT3 antiemetic drug indicated for the treatment of acute gastroenteritis and gastritis in the U.S.
• The use of a long acting oral agent to treat AGE may represent a treatment paradigm shift
• BEKINDA® 24 mg may become the new standard of care helping us treat
patients with acute gastroenteritis and gastritis quickly and effectively in the
emergency, outpatient and home settings